v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
OPERATING EXPENSES        
Research and development expenses $ 72,720 $ 31,409 $ 161,270 $ 96,352
General and administrative expenses 327,177 296,765 1,080,438 1,036,649
Total operating expenses 399,897 328,174 1,241,708 1,133,001
LOSS FROM OPERATIONS (399,897) (328,174) (1,241,708) (1,133,001)
LOSS, BEFORE TAX (399,897) (328,174) (1,241,708) (1,133,001)
NET LOSS $ (399,897) $ (328,174) $ (1,241,708) $ (1,133,001)
Net loss per share attributable to common stockholders, basic $ (0.02) $ (0.03) $ (0.08) $ (0.10)
Net loss per share attributable to common stockholders, diluted $ (0.02) $ (0.03) $ (0.08) $ (0.10)
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, basic 16,072,267 11,346,535 14,950,840 11,346,535
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, diluted 16,072,267 11,346,535 14,950,840 11,346,535